Lexaria Bioscience

🇺🇸United States

Introduction: Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Phase 1

Recruiting

Interventions: Drug: Arm 1 - DehydraTECH-CBD alone
Drug: Arm 2 - DehydraTECH-semaglutide alone
Drug: Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
Drug: Arm 4 - Rybelsus medication (semaglutide) alone
Drug: Arm 5- Tirzepatide

Locations: 🇦🇺
Paratus Clinical Pty Ltd, Blacktown Trial Clinic, Blacktown, New South Wales, Australia
🇦🇺
Emeritus - Sydney, Botany, New South Wales, Australia
🇦🇺
Sutherland Shire Clinical Research (SSCR), Miranda, New South Wales, Australia